GNOMX Corp.
Next-generation epigenetic / AI diagnostic platform for infectious disease
About
GNOMX was founded to commercialize host response epigenetic diagnostics based on research funded by a $46 million DARPA ECHO contract to an academic consortium led by the Icahn School of Medicine at Mount Sinai, Yale University School of Medicine, Princeton University, and the University of Pittsburgh School of Medicine. The DARPA-sponsored research developed patent-pending, beyond state-of-the-art blood epigenetic tests that rapidly diagnose, determine time of exposure, and monitor long-term effect of infections and other exposures.
Founders
- J. Mark Junewicz — Co-founder and CEO
- Stuart C. Sealfon, MD — Co-founder, CSO and SAB Chair
Categories
Products
Key features
Technologies
Target conditions
Care settings
Notable customers
Awards
Traction metrics
Investors
News
- J. Mark Junewicz - Co-founder and CEO of GNOMX Corp ... - LinkedIn · 2025-12-15T00:00:00.000Z
- MSIP Recognizes Researchers at Annual Innovation Awards Ceremony - Mount Sinai Innovation Partners · 2024-11-05T19:23:48.000Z
- News - Mount Sinai Innovation Partners · 2025-01-09T00:00:00.000Z
- Cancer Diagnostics Startup Imagenomix Raises $3.2M in Seed Funding | GenomeWeb · 2026-05-07T17:43:13.000Z
- CEO Welcome Message - Genome X · 2024-07-26T06:55:04.000Z
More links
Browse similar startups
Related startups
- HekaHeart — New York, NY
- i-On By Dr. Xi — New York, NY
- Ilant Health — albany, NY
- Juniper — New York, NY
- Kennar Health — Hicksville, NY
- Kins — New York, NY
- Gordion Bioscience — Boston, MA
- Helicore Biopharma — San Mateo, CA
- ImmunoMetabolix — Bridgewater, NJ
- ImYoo — Mountain View, CA
- Liberate Bio — Boston, MA
- Metanoia Bio Inc. — los angeles, CA
Profile updated Jul 29, 2026. Sources: gnomx.com


